Related Experiment Videos
Tackling intra- and inter-tumor heterogeneity to combat triple negative breast cancer
Nikita Wright1, Padmashree C G Rida2, Ritu Aneja3
1Department of Biology, Georgia State University, Atlanta, GA 30303, USA.
Abstract:
Rampant inter-patient and intra-tumor heterogeneity present formidable challenges in the clinical management of triple-negative breast cancer (TNBC) and mandate a "divide-and-conquer" approach wherein deep biomarker profiling drives patient segmentation and development of customized treatments. Genomic and proteomic studies have uncovered several TNBC subtypes each of which represents a distinct disease pathobiology and harbors unique actionable targets that may illuminate sensitivities to specific classes of therapeutics. This review details the mind-boggling complexity of TNBC, its ramifications for prognosis and therapeutic response, and discusses what treatments might befit each TNBC subtype. Additionally, focused efforts geared toward translating these findings into the clinic are urged. This review also supports an evidence-based paradigm shift towards inclusion of agents that target the mechanisms that drive intra-tumor heterogeneity, in order to improve long-term outcomes for TNBC patients.
Insights
Triple-negative breast cancer (TNBC) exhibits significant heterogeneity, necessitating personalized treatments. Biomarker profiling identifies subtypes, guiding targeted therapies for improved outcomes in TNBC management.
Area of Science:
- Oncology
- Genomics
- Proteomics
Background:
- Triple-negative breast cancer (TNBC) presents significant challenges due to inter-patient and intra-tumor heterogeneity.
- This complexity impacts prognosis and response to therapies, demanding novel clinical strategies.
- Current management often lacks tailored approaches for distinct TNBC subtypes.
Purpose of the Study:
- To review the complexity of TNBC heterogeneity and its clinical implications.
- To discuss subtype-specific pathobiology and actionable therapeutic targets.
- To advocate for biomarker-driven patient segmentation and customized treatment strategies.
Main Methods:
- Comprehensive review of genomic and proteomic studies on TNBC.
- Analysis of existing literature on TNBC subtypes and their characteristics.
- Synthesis of findings to guide therapeutic development and clinical translation.
Main Results:
- Identification of distinct TNBC subtypes based on genomic and proteomic profiles.
- Association of specific subtypes with unique pathobiology and therapeutic vulnerabilities.
- Highlighting actionable targets for targeted therapies within each subtype.
Conclusions:
- Deep biomarker profiling is crucial for segmenting TNBC patients.
- Tailored treatments based on TNBC subtypes can improve patient outcomes.
- Clinical translation of subtype-specific findings and targeting heterogeneity mechanisms are essential for advancing TNBC care.